In addition, syntaxin 6 may also serve as a potential target for drug development, thus adding to the already expanding number of agents used to treat ccRCC, as well as to the very few agents that are being developed to treat non-ccRCC histology, such as pRCC. Here, STX6 is linked to nonpapillary renal cell carcinoma.